Ligand (LGND) Q2 2026 earnings review
The Aggregation Engine Accelerates
Ligand’s pure-play royalty strategy is firing on all cylinders. Q2 2026 was a blowout: royalty revenue surged 32% to $48.0M, driving a 48% jump in Adjusted EPS to $2.37. The core commercial portfolio (Filspari, Ohtuvayre, Capvaxive) is rapidly scaling, proving that management's 2022 pivot to exit operational R&D was exactly the right move. The company secured a massive $700M at a 0% interest rate to fund future deals and closed the transformative XOMA acquisition just days after the quarter ended. Consequently, management raised the floor on full-year Adjusted EPS guidance to $9.00. The only anchor weighing down this ship is the legacy Captisol business, which continues to bleed revenue.
🐂 Bull Case
In a high-interest-rate environment, raising $700M at 0% is a massive structural advantage. This allows Ligand to outbid competitors for high-yield biotech royalties without diluting shareholders or burdening the balance sheet with interest expense.
The XOMA acquisition adds 120+ assets, including 7 commercial products (like VABYSMO). It acts as an immediate accelerant, projected to add $0.50 to EPS in 2026 and $1.50 in 2027.
🐻 Bear Case
The legacy Captisol material sales business is structurally decelerating. H1 sales fell 24% YoY. While management points to 'timing of orders,' the long-term trend is clearly stagnant.
As a passive aggregator, Ligand relies entirely on partners. Agenus just scrapped a Phase 3 trial for BOT/BAL, highlighting that even 'late-stage' assets carry heavy zero-out risks.
⚖️ Verdict: 🟢
Bullish. The 32% royalty growth is exceptional, the balance sheet is pristine, and the XOMA acquisition perfectly complements the existing compounding loop. The execution here is flawless.
Key Themes
Masterclass in Capital Allocation
Ligand pulled off a spectacular financial maneuver: issuing $700M in convertible notes due 2031 at a 0% interest rate. In today’s macro environment of elevated interest rates, securing free capital is a massive competitive moat. They instantly deployed $60M to buy back shares at $262 (offsetting dilution) and used the rest to fund the XOMA acquisition and future pipeline deals. With $1.36B in liquidity at quarter-end and $700M of deployable capital remaining post-XOMA, Ligand has the war chest to dominate the mid-cap biotech royalty space.
XOMA Integration Will Spike 2027 Earnings
The $739M acquisition of XOMA Royalty closed in July. This immediately doubles Ligand's pipeline to over 200 assets and adds critical commercial diversity (Roche’s VABYSMO, Servier’s OJEMDA). Management confidently projects this will add ~$0.50 to Adjusted EPS in the back half of 2026, and a massive $1.50 per share in 2027. Crucially, the deal brings Section 174 R&D tax credits that Ligand can utilize immediately to shield its soaring cash flows.
Commercial Blockbusters Ramping Fast
Ligand's core commercial royalties are scaling aggressively. Travere reported $141M in Q2 Filspari sales (+96% YoY) following its FDA approval for FSGS, a major label expansion. Merck reported $204M for Ohtuvayre and $184M for Capvaxive (+42%). This trio of heavy hitters is providing the predictable, high-margin cash flow necessary to fund the company's aggressive M&A strategy.
Captisol Material Sales Are a Melting Ice Cube
Despite overall corporate strength, the legacy Captisol business continues to bleed. Q2 sales were $8.0M (down from $8.3M), and year-to-date sales have plummeted 24% to $16.6M from $21.7M a year ago. Management predictably blamed the 'timing of customer orders.' This segment is no longer a growth engine and risks becoming a persistent drag on top-line optics.
G&A Expense Spikes on Dealmaking
The aggressive M&A strategy comes with a toll. General and Administrative (G&A) expenses surged 44% YoY to $29.1M in Q2. This was driven by transaction costs for XOMA, higher headcount, and rising share-based compensation. While adjusted metrics strip some of this out, actual cash is leaving the door to sustain this growth pace. Investors must monitor if this higher baseline of SG&A persists post-integration.
Clinical Attrition is Unavoidable
The royalty model requires trusting partner execution, which inevitably leads to failures. This quarter, Agenus discontinued its BATTMAN Phase 3 trial evaluating BOT/BAL in late-line metastatic colon cancer. While they plan a new neoadjuvant trial for 2027, this abruptly pushes potential revenue back by years. It is a stark reminder that even 'late-stage de-risked' assets can face zero-out scenarios.
Other KPIs
Accelerating. Adjusted net income skyrocketed 59% YoY from $32.0M. The margin profile on the royalty business is incredible—when revenue from intangible royalty assets increases by $7.3M YoY, nearly all of it falls straight to the bottom line.
GAAP Net Income was heavily distorted by a $35.7M non-cash fair value gain on Pelthos Therapeutics stock, combined with a $10.8M jump in short-term investment gains. While excluded from Adjusted EPS, this validates Ligand’s 'special situations' equity investing capability.
More than doubled YoY from $6.6M. However, this is largely artificial—driven by a $12.3M R&D funding arrangement with Orchestra BioMed rather than internal operational headcount. Ligand essentially uses the R&D line item to account for specific financing deals.
Guidance
Accelerating. Management raised the bottom end of the range from $8.50. At the $9.25 midpoint, this represents massive growth. The increase reflects XOMA synergies, interest income from the $700M debt raise, and a reduced share count from buybacks.
Stable. The top-line guidance was left completely unchanged, implying management was already baking a strong back-half into their original models. The midpoint of $290M implies roughly 25-30% growth relative to historic core metrics.
Stable. Unchanged from prior guidance. Achieving the $237.5M midpoint requires an acceleration in H2 to average ~$74M per quarter, compared to the $48M achieved in Q2. XOMA's 7 commercial products will be the key bridge to hitting this number.
Key Questions
XOMA Portfolio Trimming
You've added over 120 assets from XOMA. Historically, you've kept a lean team. How many of these early-stage or preclinical assets do you intend to actively out-license versus simply holding passively, and do you need to hire more staff to manage them?
Bridging the Royalty Guidance
H1 royalty revenue was $91M. Your FY guidance midpoint is $237.5M, requiring nearly $146M in H2. How much of this step-up is strictly from organic growth of Ohtuvayre/Filspari versus the immediate integration of XOMA's commercial assets?
Captisol Outlook
Captisol revenues are down 24% year-to-date, yet you reaffirmed the $35-$40M full-year guidance. Given that you need ~$21M in H2 to hit the midpoint, do you have binding purchase orders in hand, or is there risk to this segment's target?
Future Deployable Capital
With $700M of dry powder remaining, are you still focused on the historical run rate of $150-$250M in annual deployments, or does the 0% cost of capital encourage you to do another 'mega-deal' like XOMA in the near term?